CognitiveCare Receives a Grant of Nearly $1 Million to Advance Maternal and Fetal Health

CognitiveCare a Healthcare AI startup and pioneer in maternal and infant health, today announced it has received a $965,871 grant from the Bill & Melinda Gates Foundation to provide antenatal risk stratification AI support for the ARC’s pregnancy surveillance efforts.

According to the World Health Organization (WHO), global maternal mortality is an unacceptably high 810 deaths per day, primarily from preventable or treatable causes. Further, 10–15% of all infants born are preterm and are at increased risk of morbidity and mortality.

As part of this grant, CognitiveCare will detect and quantify propensity for critical adverse outcomes during antepartum, intrapartum, and postpartum stages, by leveraging CognitiveCare’s Maternal Infant Health Insights & Cognitive intelligence ”MIHIC” solution. MIHIC incorporates granular insights and patterns that interplay with clinical and social determinants of health to help detect and quantify risks at individual and population levels. CognitiveCare will first validate its models with local data and will then integrate MIHIC into both the Kenya PRiSMA (western Kenya) and the Aga Khan University & VITAL Pakistan ARC sites’ existing production environments. A segment of this grant is dedicated to train the ARC sites to use MIHIC, ensuring sustainable impact.

“With the foundation’s grant support, our aim is to support caregivers in understanding propensity for risk early enough to help reduce maternal and infant morbidity and mortality,” said Dr. Suresh Attili, Co-Founder and Chief Medical Officer, CognitiveCare. “Decisions on patient care rest with physicians; however, risk scores generated by MIHIC support triaging patients early. The models will further provide explainable AI functionality to help caregivers understand the ‘why’ behind each MIHIC ScoreTM.”

“Given that 94% of all maternal deaths occur in low- and lower-middle-income countries, CognitiveCare is committed to ensuring that low resource settings have access to MIHIC,” said Sheena Gill, President, Americas for CognitiveCare. “With this grant, we take another important step toward our vision to eradicate maternal and infant mortality globally.”

CognitiveCare is working at the forefront of science to build the world’s first comprehensive health risk quantification solution that integrates AI, advanced math, and stats at the intersection of medicine, biology, genomics and social determinants. CognitiveCare’s MIHIC Score™ platform assesses propensity for risk of maternal, fetal and infant health risks categorized as antepartum, intrapartum and postpartum risk scores early in the pregnancy cycle to empower proactive care.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”